IL22 and Miyoshi myopathy: Through its receptor (IL22R), IL-22 activates JAK1, tyrosine-protein kinase (Tyk)2 and MAPK signaling pathways and therefore promotes cell proliferation and drug resistance in MM via the phosphorylation of STAT3 (Figure 1).